December 29, 2022Open Access
View Full PaperBroadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)
Key Result
Inhibitors of APOC3 and ANGPTL3 are poised to enter clinical practice to reduce circulating triglycerides and potentially lower cardiovascular events.
Structured PICO
I
Intervention
Inhibitors of APOC3 and ANGPTL3 (monoclonal antibodies, antisense oligonucleotides, and silencing RNAs)
Therapies targeting APOC3 and ANGPTL3 are emerging as novel approaches to treat dyslipidemia by reducing circulating triglycerides.
Abstract
The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 (apolipoprotein C3) and ANGPTL (angiopoietin-like protein) 3 that reduce circulating triglycerides are poised to enter clinical practice. We will review the biology of how inhibition of these 2 proteins affects circulating lipoproteins as well as the current state of clinical development of monoclonal antibodies, antisense oligonucleotides, and silencing RNAs targeting APOC3 and ANGPTL3.